Beta-Amyloid-PET-Bildgebung des Gehirns

Zusammenfassung

Seit Kurzem sind mehrere Radiopharmaka für die klinische Positronen-Emissions-Tomographie (PET) von mit der Alzheimer-Krankheit assoziierten zerebralen beta-Amyloid(Aβ)-Plaques zugelassen. Mit der zunehmenden Verbreitung dieser Methode entsteht der Bedarf für entsprechende Handlungsanweisungen.

Diese S1-Leitlinie der Deutschen Gesellschaft für Nuklearmedizin beschreibt die adäquate Vorgehensweise bei der Aβ-Plaque-PET-Bildgebung. Maßnahmen zur Patientenvorbereitung, zur Anamnese-Erhebung und zu Vorsichtsmaßnahmen werden ebenso vorgestellt wie die betreffenden Radiopharmaka, Maßnahmen zur PET-Daten-Gewinnung,-Verarbeitung,-Analyse und-Befundung. Damit soll ein Beitrag zur Qualitätssicherung in der Nuklearmedizin in Deutschland geleistet werden.

Summary

Recently, a number of positron emission tomography (PET) radiotracers have been approved for clinical use. These tracers target cerebral beta-amyloid (Aβ) plaques, a hallmark of Alzheimer’s disease. Increasing use of this method implies the need for respective standards.

This German Society of Nuclear Medicine guideline describes adequate procedures for Aβ plaque PET imaging. It not only discusses the tracers used for that purpose, but also lists measures for correct patient preparation, image data generation, processing, analysis and interpretation. With that, this “S1” category (according to the German Association of the Scientific Medical Societies standard) guideline aims at contributing to quality assurance of nuclear imaging in Germany.

Schlüsselwörter

Beta-Amyloid - Plaques - Positronen-Emissions-Tomographie - PET - Leitlinie

Keywords

Beta-amyloid - plaques - positron emission tomography - PET - guideline

¹ DGN-Leitlinie (S1), Stand 10/2015 – AWMF-Registernummer: 031–052

• Literatur

• 1 Albert MS, DeKosky ST, Dickson D. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 73: 270-279.
• 2 Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
• 3 Donaghy P, Thomas AJ, O’Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry 2013; ii S1064–7481(13)00168–1.
• 4 Drzezga A. Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med 2010; 24: 55-66.
• 5 Dubois B, Feldman HH, Jacova C. et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
• 6 Dubois B, Feldman HH, Jacova C. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629.
• 7 Edison P, Rowe CC, Rinne JO. et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [¹¹C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
• 8 Formaglio M, Costes N, Seguin J. et al. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol 2011; 258: 1841-1851.
• 9 Ichise M, Liow JS, Lu JQ. et al. Linearized reference tissue parametric imaging methods: application to [¹¹C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003; 23: 1096-1112.
• 10 Johnson KA, Minoshima S, Bohnen NI. et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 2013; 54: 476-490.
• 11 Logan J, Fowler JS, Volkow ND. et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
• 12 McKhann GM, Knopman DS, Chertkow H. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-269.
• 13 Razifar P, Engler H, Ringheim A. et al. An automated method for delineating a reference region using masked volumewise principal-component analysis in ¹¹C-PIB PET. J Nucl Med Technol 2009; 37: 38-44.
• 14 Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am 2013; 97: 377-398.
• 15 Sperling RA, Aisen PS, Beckett LA. et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280-292.
• 16 Tiepolt S, Barthel H, Butzke D. et al. Influence of scan duration on the accuracy of-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging 2013; 40: 238-244.